Gini Fleming to Quality of Life
This is a "connection" page, showing publications Gini Fleming has written about Quality of Life.
Connection Strength
0.909
-
Treatment Efficacy, Adherence, and Quality of Life Among Women Younger Than 35 Years in the International Breast Cancer Study Group TEXT and SOFT Adjuvant Endocrine Therapy Trials. J Clin Oncol. 2017 Sep 20; 35(27):3113-3122.
Score: 0.342
-
Health-related quality of life outcomes for the LEAP study-CALGB 70305 (Alliance): A lymphedema prevention intervention trial for newly diagnosed breast cancer patients. Cancer. 2021 01 15; 127(2):300-309.
Score: 0.107
-
Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209). J Clin Oncol. 2020 11 20; 38(33):3841-3850.
Score: 0.107
-
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function Trial. J Clin Oncol. 2016 05 10; 34(14):1601-10.
Score: 0.078
-
Applying a conceptual model for examining health-related quality of life in long-term breast cancer survivors: CALGB study 79804. Psychooncology. 2008 Nov; 17(11):1108-20.
Score: 0.047
-
Complementary and alternative medicine use among breast cancer survivors. J Altern Complement Med. 2007 Jun; 13(5):555-62.
Score: 0.042
-
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015. Breast Cancer Res Treat. 2020 Jun; 181(3):623-633.
Score: 0.026
-
Treatment-induced symptoms, depression and age as predictors of sexual problems in premenopausal women with early breast cancer receiving adjuvant endocrine therapy. Breast Cancer Res Treat. 2020 Jun; 181(2):347-359.
Score: 0.026
-
Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer. N Engl J Med. 2019 12 19; 381(25):2403-2415.
Score: 0.025
-
Adjuvant ovarian function suppression and cognitive function in women with breast cancer. Br J Cancer. 2016 04 26; 114(9):956-64.
Score: 0.020
-
Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials. Lancet Oncol. 2015 Jul; 16(7):848-58.
Score: 0.019
-
Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med. 2014 Jul 10; 371(2):107-18.
Score: 0.017
-
The role of postoperative radiation therapy for endometrial cancer: Executive summary of an American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol. 2014 May-Jun; 4(3):137-144.
Score: 0.017
-
Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med. 2011 Dec 29; 365(26):2473-83.
Score: 0.015
-
Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA. 2009 Aug 19; 302(7):774-80.
Score: 0.012
-
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol. 2004 Jun 01; 22(11):2061-8.
Score: 0.009